Covid-19 Innovation Challenges by Innoget

Expertise in molecular biology either experimentally or computationally

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Research Services and Capabilities · United Kingdom

Summary of the technology

The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results.

At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise:

• Bioinformatics
• Cellular Biology
• Structural Biology
• Genomics
• Immunology
• Microbiology
• Proteomics.

This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Covid-19 Innovation Challenges by Innoget

Description of the technology

Among others, the Institut de Biotecnologia i de Biomedicina (IBB) can help with the Covid19 emergency by providing expertise in the following research areas:

  • Antibody/protein production
  • Lateral flow diagnostic System
  • Genomic variation analysis, database creation, association studies/big data analysis.
  • Drug design/screening; molecular docking, quantum physics: for target-drug screening, improving efficiency or attachment, etc.
  • Cristallography
  • Design and production of nanoproteins or nanopeptides as disease treatment/diagnostic.
  • Vaccine development, improvement of affinity, etc.
  • Experimental validations of vaccine-antigen/ target-drug (interaction validation techniques)
  • Understanding/Modulation of the immune system

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Related keywords

  • Pharmaceutics
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Clinical Research, Trials
  • Diagnostics, Diagnosis
  • Pharmaceutical Products / Drugs
  • Biology / Biotechnology
  • Biochemistry / Biophysics Technology
  • Cellular and Molecular Biology Technology
  • Genetic Engineering Technology
  • Microbiology Technology
  • Molecular design Technology
  • Enzyme Technology
  • Protein Engineering
  • Genome Research
  • Remote diagnostics
  • Enzymology/Protein Engineering/Fermentation
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Pharmaceuticals/fine chemicals
  • antibody
  • immune system
  • coronavirus
  • covid19
  • covid
  • disease treatment
  • cristallogrpahy

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.